U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861088) titled 'The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer' on Feb. 28.
Brief Summary: The aim of this Phase 3 study is to evaluate the efficacy of isoquercetin as compared to the placebo in prevention of thromboembolic events in patients with metastatic pancreatic cancer.
Study Start Date: June 30, 2025
Study Type: INTERVENTIONAL
Condition:
Venous Thromboembolism
Metastatic Pancreatic Cancer
Intervention:
DRUG: Isoquercetin
Isoquercetin with vitamin C and vitamin B3 capsules
DRUG: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Quercis Pharma AG
Published by HT Digi...